Pumactant
Alternative Names: AdSurf; ALEC; Artificial lung expanding compound; ZofacLatest Information Update: 15 Oct 2020
Price :
$50 *
At a glance
- Originator Britannia Pharmaceuticals
- Class Phospholipids; Pulmonary surfactants
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Market Withdrawal Neonatal respiratory distress syndrome
- No development reported Post-surgical adhesions
- Discontinued Asthma; Respiratory tract disorders
Most Recent Events
- 02 Oct 2020 Britannia Pharmaceuticals has been acquired by STADA Arzneimittel
- 08 Sep 2009 Discontinued - Phase-II for Asthma in United Kingdom (Inhalation)
- 08 Sep 2009 Discontinued - Preclinical for Respiratory tract disorders in United Kingdom (unspecified route)